The first reported potent and selective IKK alpha inhibitors, with the lead compound achieving 60% tumour growth inhibition
Technology Overview
Scientists at Strathclyde have developed the first reported potent and selective IKK alpha inhibitors, and the lead compound has been shown to achieve 60% tumour growth inhibition in the metastatic PC3m xenograph prostate cancer model, despite its current sub-optimal PK (optimisation is ongoing). Consistent with this, in vitro studies have demonstrated a reduction in androgen receptor levels. Intriguingly, our scientists have identified a major cohort of prostate cancer patients with a specific molecular marker who have a significantly worse prognosis and in which an IKKα inhibitor could therefore potentially be of particular therapeutic benefit. This may enable an informative early-stage trial design (further data available under CDA).